PartnershipAug 4, 2026, 04:38 PM
Splash Beverage Group Partners Lupvindol for CannEpil® Animal Drug Dev
AI Summary
Splash Beverage Group entered a Development and Collaboration Agreement with Lupvindol Biosciences Ltd. to develop CannEpil®, a cannabinoid-based pharmaceutical product, as an Investigational Veterinary Product for companion-animal oncology and chronic pain management. Lupvindol will lead FDA regulatory activities and product development, while Splash will provide milestone funding totaling up to $1.115 million and an ongoing 4% royalty on net sales. The agreement aims for Conditional Approval of the new animal drug.
Key Highlights
- Splash Beverage Group partnered with Lupvindol Biosciences for CannEpil® animal drug development.
- Lupvindol will lead FDA regulatory activities for the Investigational Veterinary Product.
- Splash to provide $95,000 upon agreement execution.
- Total milestone funding up to $1.115 million for Conditional Approval.
- Splash to pay 4% royalty on net sales of the Product for 10 years.
- CannEpil® targets companion-animal oncology and chronic pain management.
- Lupvindol may elect to receive common stock in lieu of royalty payments.
- Initial term of the Collaboration Agreement is five years.
Price Impact
More from SBEV